23:25 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Amplyx reports Phase I data for APX001 in fungal infections

In October, Amplyx Pharmaceuticals Inc. (San Diego, Calif.) reported data from two Phase I trials in 166 healthy volunteers showing that oral and IV APX001 were well tolerated at all doses tested. Additionally, the company...
20:40 , Aug 2, 2017 |  BC Extra  |  Financial News

Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital, and existing...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

IV APX001: Phase I started

Amplyx began a double-blind, placebo-controlled, dose-escalation, European Phase I trial to evaluate single and multiple doses of IV APX001 in about 80 healthy volunteers. The company plans to begin Phase I testing of oral APX001...